Association of the PPP3CA c.249G>A variant with clinical outcomes of tacrolimus-based therapy in kidney transplant recipients
Pharmgenomics Pers Med
; 10: 101-106, 2017. tab
Article
en En
| SES-SP, SESSP-IDPCPROD, SES-SP
| ID: biblio-1065491
Biblioteca responsable:
BR79.1
Ubicación: BR79.1
ABSTRACT
BACKGROUND:
The effects of genetic variants related to the pharmacodynamic mechanisms of immunosuppressive drugs on their therapeutic efficacy and safety have been poorly explored. This study was performed to investigate the influence of the PPP3CA c.249G>A variant on the clinical outcomes of kidney transplant recipients.PATIENTS ANDMETHODS:
A total of 148 Brazilian patients received tacrolimus (TAC)-based immunosuppressive therapy for 90 days post-kidney transplantation. The PPP3CA rs3730251 (c.249G>A) polymorphism was determined by real-time polymerase chain reaction. Single-nucleotide polymorphism (SNP) data for CYP3A5 rs776746 (CYP3A5*3C; g.6986A>G) were used to eliminate the confounding effects of this variant.Palabras clave
Texto completo:
1
Colección:
06-national
/
BR
Base de datos:
SES-SP
/
SESSP-IDPCPROD
Asunto principal:
Trasplante de Riñón
/
Tacrolimus
Tipo de estudio:
Risk_factors_studies
Idioma:
En
Revista:
Pharmgenomics Pers Med
Año:
2017
Tipo del documento:
Article